Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | RAD51 | Q06609 | 3/20 | 0.37 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.37 |
| ▸ | APP | P05067 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPM1 | P06748 | 3/20 | 0.35 |
| ▸ | ALK | Q9UM73 | 3/20 | 0.35 |
| ▸ | TERT | O14746 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31031257 | 0.82 | ALDH1A1 (0.41) | ALDH1A1NPC1TP53MAPTALOX15 | |
| SCHEMBL19714764 | 0.82 | APP (0.40) | RAD51TLR9APPALDH1A1NPC1 | |
| SCHEMBL19714775 | 0.80 | ALDH1A1 (0.45) | ALDH1A1NPC1TP53MAPTALOX15 | |
| SCHEMBL19714778 | 0.77 | RAD51 (0.42) | RAD51TLR9APPALDH1A1NPC1 | |
| SCHEMBL19714765 | 0.77 | ALK (0.49) | RAD51ALDH1A1NPC1TP53MAPT | |
| SCHEMBL23917383 | 0.73 | KDR (0.48) | ALDH1A1NPC1MAPTMAPK1RAB9A | |
| SCHEMBL19735198 | 0.73 | KDM4E (0.60) | ALDH1A1NPC1TP53MAPTALOX15 | |
| SCHEMBL31031228 | 0.69 | ALDH1A1 (0.32) | ALDH1A1NPC1TP53MAPTALOX15 | |
| SCHEMBL31031218 | 0.69 | SUV39H2 (0.34) | ALDH1A1NPC1TP53MAPTALOX15 | |
| SCHEMBL21623397 | 0.68 | ALK (0.48) | RAD51ALDH1A1NPC1MAPTALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3339309-B1 | RADIOACTIVE HALOGEN-LABELED PYRIDO[1,2-A]BENZIMIDAZOLE DERIVATIVE COMPOUND | UNIV KYOTO (JP) | 2020-04-29 | — | — | EP | disclosed |
| US-10081630-B2 | Radioactive halogen-labeled pyrido [1,2-A] benzimidazole derivative compound | KYOTO UNIVERSITY (JP) | 2018-09-25 | — | — | US | disclosed |
| EP-3339309-A1 | RADIOACTIVE HALOGEN-LABELED PYRIDO[1,2-A]BENZIMIDAZOLE DERIVATIVE COMPOUND | Kyoto University (JP) | 2018-06-27 | — | — | EP | disclosed |
| US-20170362226-A1 | RADIOACTIVE HALOGEN-LABELED PYRIDO [1,2-A] BENZIMIDAZOLE DERIVATIVE COMPOUND | KYOTO UNIVERSITY (JP) | 2017-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10081630-B2 | Radioactive halogen-labeled pyrido [1,2-A] benzimidazole derivative compound | BRI3BP, BRD1, BRDT | SLC6A2 618/4885RAD51 1381/4885TLR9 4780/4885 |
| US-20170362226-A1 | RADIOACTIVE HALOGEN-LABELED PYRIDO [1,2-A] BENZIMIDAZOLE DERIVATIVE COMPOUND | BRI3BP, BRD1, BRDT | SLC6A2 618/4885RAD51 1381/4885TLR9 4780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.